schliessen

Filtern

 

Bibliotheken

Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis

Glypican-3 (GPC3) is a promising tumor marker for hepatocellular carcinoma (HCC) diagnosis with high sensitivity and specificity. The aim of this study was to establish an immunohistochemical detection method for GPC3 using the 7D11 monoclonal antibody (7D11 mAb) and evaluate its application for HCC... Full description

Journal Title: Science China Life Sciences 2013, Vol.56(3), pp.234-239
Main Author: Yu, JuanPing
Other Authors: Ma, Qiang , Zhang, Bin , Ma, RuiJuan , Xu, XiGuang , Li, MingSong , Xu, WeiWen , Li, Ming
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1674-7305 ; E-ISSN: 1869-1889 ; DOI: 10.1007/s11427-013-4451-y
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: springer_jour10.1007/s11427-013-4451-y
title: Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis
format: Article
creator:
  • Yu, JuanPing
  • Ma, Qiang
  • Zhang, Bin
  • Ma, RuiJuan
  • Xu, XiGuang
  • Li, MingSong
  • Xu, WeiWen
  • Li, Ming
subjects:
  • glypican-3
  • 7D11 monoclonal antibody
  • hepatocellular carcinoma
  • immunohistochemistry
ispartof: Science China Life Sciences, 2013, Vol.56(3), pp.234-239
description: Glypican-3 (GPC3) is a promising tumor marker for hepatocellular carcinoma (HCC) diagnosis with high sensitivity and specificity. The aim of this study was to establish an immunohistochemical detection method for GPC3 using the 7D11 monoclonal antibody (7D11 mAb) and evaluate its application for HCC diagnosis. The feasibility of the 7D11 mAb was evaluated by immunohistochemistry performed on adjacent normal liver and intrahepatic cholangiocarcinoma (ICC) samples, Furthermore, the serum GPC3 levels were evaluated in 40 HCC patients, 7 ICC patients and 50 healthy donors. The results showed that GPC3 was expressed in 85% of HCC tissues (34/40), but was undetectable in ICC tissues and adjacent normal tissues.GPC3 was significantly increased in the serum of HCC patients (17/40, 42.5%) but was undetectable in the serum of ICC patients (0/7, 0%) and healthy donors(0/50, 0%). This prospective study evaluated the clinical usefulness of 7D11 mAb for GPC3 detection in HCC patients. In conclusion, the use of 7D11 mAb might be good for GPC3 large-scale applications for clinical diagnosis of HCC.
language: eng
source:
identifier: ISSN: 1674-7305 ; E-ISSN: 1869-1889 ; DOI: 10.1007/s11427-013-4451-y
fulltext: fulltext_linktorsrc
issn:
  • 1869-1889
  • 18691889
  • 1674-7305
  • 16747305
url: Link


@attributes
ID1574035833
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1007/s11427-013-4451-y
sourceidspringer_jour
recordidTN_springer_jour10.1007/s11427-013-4451-y
sourcesystemPC
pqid1318944458
galeid329054886
display
typearticle
titleClinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis
creatorYu, JuanPing ; Ma, Qiang ; Zhang, Bin ; Ma, RuiJuan ; Xu, XiGuang ; Li, MingSong ; Xu, WeiWen ; Li, Ming
ispartofScience China Life Sciences, 2013, Vol.56(3), pp.234-239
identifier
subjectglypican-3 ; 7D11 monoclonal antibody ; hepatocellular carcinoma ; immunohistochemistry
descriptionGlypican-3 (GPC3) is a promising tumor marker for hepatocellular carcinoma (HCC) diagnosis with high sensitivity and specificity. The aim of this study was to establish an immunohistochemical detection method for GPC3 using the 7D11 monoclonal antibody (7D11 mAb) and evaluate its application for HCC diagnosis. The feasibility of the 7D11 mAb was evaluated by immunohistochemistry performed on adjacent normal liver and intrahepatic cholangiocarcinoma (ICC) samples, Furthermore, the serum GPC3 levels were evaluated in 40 HCC patients, 7 ICC patients and 50 healthy donors. The results showed that GPC3 was expressed in 85% of HCC tissues (34/40), but was undetectable in ICC tissues and adjacent normal tissues.GPC3 was significantly increased in the serum of HCC patients (17/40, 42.5%) but was undetectable in the serum of ICC patients (0/7, 0%) and healthy donors(0/50, 0%). This prospective study evaluated the clinical usefulness of 7D11 mAb for GPC3 detection in HCC patients. In conclusion, the use of 7D11 mAb might be good for GPC3 large-scale applications for clinical diagnosis of HCC.
languageeng
source
version7
oafree_for_read
lds50peer_reviewed
links
openurl$$Topenurl_article
linktorsrc$$Uhttp://dx.doi.org/10.1007/s11427-013-4451-y$$EView_full_text_in_Springer
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Yu, JuanPing
1Ma, Qiang
2Zhang, Bin
3Ma, RuiJuan
4Xu, XiGuang
5Li, MingSong
6Xu, WeiWen
7Li, Ming
titleClinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis
descriptionGlypican-3 (GPC3) is a promising tumor marker for hepatocellular carcinoma (HCC) diagnosis with high sensitivity and specificity. The aim of this study was to establish an immunohistochemical detection method for GPC3 using the 7D11 monoclonal antibody (7D11 mAb) and evaluate its application for HCC diagnosis. The feasibility of the 7D11 mAb was evaluated by immunohistochemistry performed on adjacent normal liver and intrahepatic cholangiocarcinoma (ICC) samples, Furthermore, the serum GPC3 levels were evaluated in 40 HCC patients, 7 ICC patients and 50 healthy donors. The results showed that GPC3 was expressed in 85% of HCC tissues (34/40), but was undetectable in ICC tissues and adjacent normal tissues.GPC3 was significantly increased in the serum of HCC patients (17/40, 42.5%) but was undetectable in the serum of ICC patients (0/7, 0%) and healthy donors(0/50, 0%). This prospective study evaluated the clinical usefulness of 7D11 mAb for GPC3 detection in HCC patients. In conclusion, the use of 7D11 mAb might be good for GPC3 large-scale applications for clinical diagnosis of HCC.
subject
0glypican-3
17D11 monoclonal antibody
2hepatocellular carcinoma
3immunohistochemistry
general
010.1007/s11427-013-4451-y
1English
2Springer Science & Business Media B.V.
3SpringerLink Open Access
sourceidspringer_jour
recordidspringer_jour10.1007/s11427-013-4451-y
issn
01869-1889
118691889
21674-7305
316747305
rsrctypearticle
creationdate2013
addtitle
0Science China Life Sciences
1Sci. China Life Sci.
searchscopespringer_free
scopespringer_free
lsr30VSR-Enriched:[pages, galeid, pqid]
sort
titleClinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis
authorYu, JuanPing ; Ma, Qiang ; Zhang, Bin ; Ma, RuiJuan ; Xu, XiGuang ; Li, MingSong ; Xu, WeiWen ; Li, Ming
creationdate20130300
facets
frbrgroupid7708058318366350614
frbrtype5
languageeng
creationdate2013
topic
0Glypican-3
17d11 Monoclonal Antibody
2Hepatocellular Carcinoma
3Immunohistochemistry
collectionSpringerLink Open Access
prefilterarticles
rsrctypearticles
creatorcontrib
0Yu, JuanPing
1Ma, Qiang
2Zhang, Bin
3Ma, RuiJuan
4Xu, XiGuang
5Li, MingSong
6Xu, WeiWen
7Li, Ming
jtitleScience China Life Sciences
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
aulast
0Yu
1Ma
2Zhang
3Xu
4Li
aufirst
0JuanPing
1Qiang
2Bin
3RuiJuan
4XiGuang
5MingSong
6WeiWen
7Ming
au
0Yu, JuanPing
1Ma, Qiang
2Zhang, Bin
3Ma, RuiJuan
4Xu, XiGuang
5Li, MingSong
6Xu, WeiWen
7Li, Ming
atitleClinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis
jtitleScience China Life Sciences
stitleSci. China Life Sci.
risdate201303
volume56
issue3
spage234
epage239
issn1674-7305
eissn1869-1889
genrearticle
ristypeJOUR
abstractGlypican-3 (GPC3) is a promising tumor marker for hepatocellular carcinoma (HCC) diagnosis with high sensitivity and specificity. The aim of this study was to establish an immunohistochemical detection method for GPC3 using the 7D11 monoclonal antibody (7D11 mAb) and evaluate its application for HCC diagnosis. The feasibility of the 7D11 mAb was evaluated by immunohistochemistry performed on adjacent normal liver and intrahepatic cholangiocarcinoma (ICC) samples, Furthermore, the serum GPC3 levels were evaluated in 40 HCC patients, 7 ICC patients and 50 healthy donors. The results showed that GPC3 was expressed in 85% of HCC tissues (34/40), but was undetectable in ICC tissues and adjacent normal tissues.GPC3 was significantly increased in the serum of HCC patients (17/40, 42.5%) but was undetectable in the serum of ICC patients (0/7, 0%) and healthy donors(0/50, 0%). This prospective study evaluated the clinical usefulness of 7D11 mAb for GPC3 detection in HCC patients. In conclusion, the use of 7D11 mAb might be good for GPC3 large-scale applications for clinical diagnosis of HCC.
copBeijing
pubScience China Press
doi10.1007/s11427-013-4451-y
pages234-239
oafree_for_read
date2013-03